Publication Name	World Journal of Gastroenterology
Manuscript ID	81641
Country	China

Received	2022-11-29 09:50
Peer-Review Started	2022-11-29 09:51
To Make the First Decision
Return for Revision	2022-12-19 23:29
Revised	2022-12-25 07:35
Second Decision	2023-03-20 03:15
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-03-20 09:29
Articles in Press	2023-03-20 09:29
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-03-26 15:12
Publish the Manuscript Online	2023-04-07 05:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Interferon-lambda: New role in intestinal symptoms of COVID-19
Manuscript Source	Invited Manuscript
All Author List	Yi-Yang Pan, Liu-Can Wang, Feng Yang and Min Yu
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China (to M.Y.) 81970468
Corresponding Author	Min Yu, PhD, Professor, Department of General Surgery, Chongqing general Hospital, No. 118 Xingguang Avenue, Liangjiang New District, Chongqing 400013, China. yumimianbao@163.com
Key Words	COVID-19; SARS-CoV-2; Interferon-λ; Gastrointestinal infection; Mechanism; Anti-viral response
Core Tip	The tremendous public health and economic impact of the coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a huge challenge for countries across the whole world. Increased evidences have revealed that SARS-CoV-2 also induced intestinal infection. Type III interferon (IFN), also called IFN-λ, plays an antiviral role in intestinal infection, and has focused, long-lasting, as well as non-inflammatory characteristics. In this review, we summarized the invasion and immune escape mechanisms of the SARS-CoV-2. Furthermore, we concerned about the gastrointestinal impact of the SARS-CoV-2 and the comprehensive role of IFN-λ, also called type III IFN, in anti-enteric SARS-CoV-2 infection.
Publish Date	2023-04-07 05:51
Citation	Pan YY, Wang LC, Yang F, Yu M. Interferon-lambda: New role in intestinal symptoms of COVID-19. World J Gastroenterol 2023; 29(13): 1942-1954
URL	https://www.wjgnet.com/1007-9327/full/v29/i13/1942.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i13.1942

Full Article (PDF)	WJG-29-1942.pdf
Full Article (Word)	WJG-29-1942.docx
Manuscript File	81641_Auto_Edited-JLW.docx
Answering Reviewers	81641-Answering reviewers.pdf
Audio Core Tip	81641-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	81641-Conflict-of-interest statement.pdf
Copyright License Agreement	81641-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	81641-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	81641-Language certificate.pdf
Supplementary Material	81641-Supplementary material.pdf
Peer-review Report	81641-Peer-review(s).pdf
Scientific Misconduct Check	81641-Bing-Fan JR-2.png
Scientific Editor Work List	81641-Scientific editor work list.pdf
CrossCheck Report	81641-CrossCheck.png
CrossCheck Report	81641-CrossCheck report.pdf